2029, FDA and Patients - Pharma Rep Focus

Research predicts 2029 small molecule oncology market leaders

European Pharmaceutical Review

OCTOBER 12, 2023

Strong demand for small molecules as treatment for non-small cell lung cancer (NSCLC) in the eight major markets means that the small molecule treatment market for the disease is expected to reach over $15 billion by 2029. billion and a market share of 17 percent by 2029, GlobalData predicted. percent by 2029.

Marketing

Marketing Sales Medicine FDA

What sets the Drugs to Watch in 2024 apart

Clarivate

JANUARY 8, 2024

These new treatments hold tremendous promise to advance patient care and fuel the next generation of medical breakthroughs. Clarivate data indicates a 90% probability that datopotamab deruxtecan will win marketing authorization in the United States, and projects 2029 sales of $2.7 billion in 2029 for CASGEVY alone. Granted U.S.

Marketing

Marketing Patients Healthcare Healthcare

US legislation to benefit small molecule drug innovation

European Pharmaceutical Review

FEBRUARY 5, 2024

As a “vital class of treatments” for patients worldwide, King considered that the new legislation would “fix a section of the US Inflation Reduction Act (IRA) and make certain that we are not disincentivising the development of small molecule drugs that are often more accessible for patients”.

Food and Drug Administration

Food and Drug Administration Medicine Food Pharmaceutical

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

Pharmaceutical Technology

APRIL 28, 2023

FDA approval follows the successful outcomes of the Sustain Forte trial (NCT03989232), the results of which displayed a superior reduction in HbA1c levels with once-weekly semaglutide 2.0mg, in comparison to once-weekly semaglutide 1.0mg, among individuals suffering from type 2 diabetes.

Sales

Sales Marketing Medical Patients

NICE recommends AbbVie’s/J&J’s Imbruvica for combo use in untreated CLL

Pharmaceutical Technology

APRIL 24, 2023

There, the data shows that patients on this regimen live longer lives along with having a greater period of time before disease progression, than with other treatments. CLL is regarded as the most common type of leukaemia in England where 3,157 patients were diagnosed with the disease in 2017, based on the institute’s announcement.

Food and Drug Administration

Food and Drug Administration Side effects Sales Food

Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3

pharmaphorum

OCTOBER 26, 2022

The first patient has already been enrolled into its FIBRONEER phase 3 programme for BI 1015550, which already has a breakthrough designation from the FDA after a positive phase 2 trial showed improved lung function in patients with IPF over a 12-week period.

Recruitment

Recruitment Prospecting Marketing Patients

Scorpion inks deal with Pierre Fabre for next-gen EGFR inhibitors

Pharmaceutical Technology

APRIL 4, 2023

of NSCLC patients with exon 19 and 21 mutations develop resistance mutations at C797S. The Boston, Massachusetts-based Scorpion expects to submit an investigational new drug (IND) application for STX-721 to the US Food and Drug Administration (FDA) in mid-2023, with an IND application for STX-241 expected in H1 2024. billion in 2029.

Food and Drug Administration

Food and Drug Administration Biopharma FDA Pharmaceutical

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

JANUARY 10, 2023

Many of the current existing therapies are often viewed by physicians as not optimal to addressing the needs of patients, and challenges remain such as improving patient compliance, safety profile, and addressing comorbidities of T2D. billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%.

Marketing

Marketing Physicians Leads Sales

AstraZeneca acquires TeneoTwo in $1.3bn deal to broaden haematology portfolio

Pharmaceutical Technology

JULY 8, 2022

In December 2014, Amgen’s landmark FDA approval saw Blincyto (blinatumomab) approved for relapsed/refractory (R/R) B-cell progenitor acute lymphoblastic leukaemia (B-ALL), at the time being the only marketed BiTE. Currently, there are 110 BiTEs in oncology clinical trials, with seven in Phase III and three in pre-registration. months vs. 4.0

Safety

Safety Sales Marketing Patients

mRNA cancer vaccine granted world-first approval

European Pharmaceutical Review

MAY 10, 2024

The US Food and Drug Administration (FDA) has granted the first approval of an Epstein–Barr virus-related mRNA therapeutic cancer vaccine. The US Food and Drug Administration (FDA) has granted the first approval of an Epstein–Barr virus-related mRNA therapeutic cancer vaccine. billion by 2029.

Food and Drug Administration

Food and Drug Administration FDA Marketing Food

Oncology biosimilar case studies: rituximab biosimilars

Pharmaceutical Technology

MAY 19, 2023

Rituxan received its first FDA approval in 1997 for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and reached peak global sales of $7.5bn in 2014. Given the lower price of biosimilars, the patient share will be even higher than the market share, meaning that over 80% of US patients will have switched to biosimilar rituximab by 2029.

Sales

Sales Competition Marketing Patients

EHA 2023: Kura Oncology’s menin inhibitor ziftomenib shows impressive Phase I results

Pharmaceutical Technology

JUNE 13, 2023

The agent is being evaluated in relapsed/refractory (R/R) patients who have KMT2A-rearranged (KMT2ar) or NPM1-mutant (NPM1m) acute myeloid leukaemia (AML). Ziftomenib targets the menin-KMT2a protein-protein interaction that may occur in patients with KMT2ar or NPM1m genetic alterations. months for all patients achieving CRc.

Patients

Patients Sales Competition Safety

The future of pain medication: are cannabinoids the solution to the opioid epidemic?

Pharmaceutical Technology

JUNE 12, 2023

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. A promising example includes Vertex Pharmaceuticals’s VX-548, a sodium channel subunit blocker. Six cannabinoids have recently completed or are undergoing Phase II trials.

Medical

Medical Prescription Management Manufacturing

Expectations rise for gene therapy to change treatment landscape

pharmaphorum

AUGUST 31, 2022

In recent years, gene therapy has transitioned from a promising idea to a reality for patients, with many of the severe safety issues that emerged in early iterations of the technology being overcome. from 2021 to 2029. FDA backing. A broadening pipeline.

FDA

FDA Marketing Safety Patients

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

OCTOBER 17, 2022

billion by 2029. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. The device replaces a connecting bone in the ankle joint and can be customized according to patient preference.

Medical

Medical Food and Drug Administration Healthcare Healthcare

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

OCTOBER 17, 2022

billion by 2029. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. The device replaces a connecting bone in the ankle joint and can be customized according to patient preference.

Medical

Medical Food and Drug Administration Healthcare Healthcare

Intercept receives orphan drug designation for liver disease combo therapy

Pharmaceutical Technology

MAY 17, 2023

The US Food and Drug Administration (FDA) has awarded an orphan drug designation to Intercept Pharmaceuticals’ fixed-dose combination of obeticholic acid and bezafibrate for the treatment of primary biliary cholangitis. Data from the analyses will be used for a potential end-of-Phase II study meeting with the FDA. billion in 2029.

Food and Drug Administration

Food and Drug Administration FDA Pharmaceutical Prospecting

Pharma Rep Focus

Research predicts 2029 small molecule oncology market leaders

What sets the Drugs to Watch in 2024 apart

Trending Sources

US legislation to benefit small molecule drug innovation

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

NICE recommends AbbVie’s/J&J’s Imbruvica for combo use in untreated CLL

Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3

Scorpion inks deal with Pierre Fabre for next-gen EGFR inhibitors

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

AstraZeneca acquires TeneoTwo in $1.3bn deal to broaden haematology portfolio

mRNA cancer vaccine granted world-first approval

Oncology biosimilar case studies: rituximab biosimilars

EHA 2023: Kura Oncology’s menin inhibitor ziftomenib shows impressive Phase I results

The future of pain medication: are cannabinoids the solution to the opioid epidemic?

Expectations rise for gene therapy to change treatment landscape

Emerging Trends in Orthopedic Medical Device Industry

Emerging Trends in Orthopedic Medical Device Industry

Intercept receives orphan drug designation for liver disease combo therapy

Stay Connected